These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 29274022)

  • 1. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Ranibizumab versus Aflibercept in Treating Macular Edema among Patients with Serous Retinal Detachment Secondary to Branch Retinal Vein Occlusion.
    Küçük B; Sirakaya E; Karaca C
    Ocul Immunol Inflamm; 2021 Feb; 29(2):403-410. PubMed ID: 31718358
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Li F; Sun M; Guo J; Ma A; Zhao B
    Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
    Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
    Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
    Son BK; Kwak HW; Kim ES; Yu SY
    Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
    Spooner K; Hong T; Fraser-Bell S; Chang AA
    Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
    JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!
    Alforja S; Hunt A; Nguyen V; O'Toole L; Gabrielle PH; Invernizzi A; Mehta H; Ponsioen TL; Squirrell D; Casaroli-Marano RP; Barthelmes D; Gillies MC; Zarranz-Ventura J;
    Ophthalmol Retina; 2024 Oct; 8(10):962-970. PubMed ID: 38641007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.